|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...118119120121122123124125126127128...156157» |
- Trial completion: cLDL in RA: Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=100, Completed, Sponsor: University of Arkansas
Active, not recruiting --> Completed
- Trial completion: Rheumatoid Arthritis Comorbidity: Bone Health in Men and African Americans (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=1745, Completed, Sponsor: University of Nebraska
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: Gene-Environment Interactions in Rheumatoid Arthritis Autoimmunity Disease Severity (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=800, Completed, Sponsor: University of Nebraska
Recruiting --> Completed Recruiting --> Completed
- New P2 trial: Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects (clinicaltrials.gov) - Jun 17, 2013
P2, N=40, Suspended, Sponsor: University Hospital of Ferrara
- ||| Biomarker, Enrollment open: An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=80, Enrolling by invitation, Sponsor: Novo Nordisk
Recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- Enrollment open: Telehealth Intervention for Youth With T1DM (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=110, Recruiting, Sponsor: Children's Hospital Boston
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Enrollment closed: A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy (clinicaltrials.gov) - Jun 17, 2013
P2, N=274, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | NI-071 (infliximab biosimilar) - Sanofi, Nichi / Iko, Binex, Aprogen, Elea Labs
Trial completion: Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 17, 2013
P1, N=14, Completed, Sponsor: Nichi-Iko Pharmaceutical Co.,Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST) (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=322, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: CAMEO: Canadian Methotrexate and Etanercept Outcome Study (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=257, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Rituxan (rituximab) / Roche
Trial completion: A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy. (clinicaltrials.gov) - Jun 17, 2013
P3, N=215, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Avonex (recombinant IFN-?-1a) / Biogen
Enrollment change, Combination therapy: Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis (clinicaltrials.gov) - Jun 16, 2013
P2, N=43, Completed, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed N=60 --> 43
- Oshadi Icp (insulin oral) / Oshadi Drug Administration
Trial completion: Safety and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study (clinicaltrials.gov) - Jun 16, 2013
P1/2, N=10, Completed, Sponsor: Oshadi Drug Administration
N=60 --> 43 Recruiting --> Completed
- |||| BMS-817399 / BMS
Trial completion: Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jun 16, 2013
P2, N=123, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Recruiting --> Completed
- | Avonex (recombinant IFN-?-1a) / Biogen
Trial completion, Combination therapy: Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis (clinicaltrials.gov) - Jun 16, 2013
P2, N=43, Completed, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Completed Active, not recruiting --> Completed
- | tabalumab (LY2127399) / Eli Lilly
Biomarker, Trial completion, Biopsy: A Study of LY2127399 in Rheumatoid Arthritis (clinicaltrials.gov) - Jun 12, 2013
P2, N=36, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Promacta (eltrombopag) / Novartis
Enrollment change: LENS - Long-term Eltrombopag Observational Study (clinicaltrials.gov) - Jun 12, 2013
P2, N=164, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=350 --> 164
- Actemra IV (tocilizumab) / Roche, JW Pharma
New P4 trial, Combination therapy: A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs (clinicaltrials.gov) - Jun 12, 2013
P4, N=0, Withdrawn, Sponsor: Hoffmann-La Roche
- | AMP-110 / AstraZeneca, Daiichi Sankyo
New P1 trial: Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 12, 2013
P1, N=21, Active, not recruiting, Sponsor: Amplimmune
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Enrollment closed: Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Jun 12, 2013
P2, N=232, Active, not recruiting, Sponsor: GlaxoSmithKline
N=350 --> 164 Recruiting --> Active, not recruiting
- |||| Promacta (eltrombopag) / Novartis
Trial completion: LENS - Long-term Eltrombopag Observational Study (clinicaltrials.gov) - Jun 12, 2013
P2, N=164, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Tysabri (natalizumab) / Biogen, Royalty
Trial completion: Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control (clinicaltrials.gov) - Jun 11, 2013
P=N/A, N=164, Completed, Sponsor: John F. Foley, MD
Active, not recruiting --> Completed Recruiting --> Completed
- decitabine / Generic mfg.
Trial initiation date: A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia (clinicaltrials.gov) - Jun 11, 2013
P2, N=60, Recruiting, Sponsor: Shandong University
Recruiting --> Completed Initiation date: Jun 2012 --> Jun 2013
- ||| Enbrel (etanercept) / Pfizer, Amgen
Clinical: Study to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria (clinicaltrials.gov) - Jun 11, 2013
P=N/A, N=120, Recruiting, Sponsor: Pfizer
- decitabine / Generic mfg.
Enrollment open: A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia (clinicaltrials.gov) - Jun 11, 2013
P2, N=60, Recruiting, Sponsor: Shandong University
Initiation date: Jun 2012 --> Jun 2013 Not yet recruiting --> Recruiting
- Trial termination: More Added Value of Therapeutic Education in the Management of Patients With Rheumatoid Arthritis (ETP-PR) (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=62, Terminated, Sponsor: Nantes University Hospital
Not yet recruiting --> Recruiting Completed --> Terminated
- || Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=1014, Completed, Sponsor: Pfizer
Completed --> Terminated N=487 --> 1014
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept (clinicaltrials.gov) - Jun 10, 2013
P4, N=217, Active, not recruiting, Sponsor: Amgen
- Enrollment change: Functional and Physiological Responses to Lokomat Therapy (Pilot Study) (clinicaltrials.gov) - Jun 9, 2013
P=N/A, N=27, Completed, Sponsor: Department of Veterans Affairs
N=487 --> 1014 N=80 --> 27
- || Enrollment change: PAS:IDE: Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects (clinicaltrials.gov) - Jun 9, 2013
P=N/A, N=350, Enrolling by invitation, Sponsor: Corin
N=80 --> 27 N=450 --> 350
- ||||| Cosentyx (secukinumab) / Novartis
New P2 trial: Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jun 9, 2013
P2, N=380, Recruiting, Sponsor: Novartis Pharmaceuticals
- Enrollment open: Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Jun 8, 2013
P=N/A, N=135, Recruiting, Sponsor: Keesler Air Force Base Medical Center
N=450 --> 350 Not yet recruiting --> Recruiting
- ||||| dimethyl fumarate / Generic mfg.
New P4 trial: MANAGE: Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States (clinicaltrials.gov) - Jun 6, 2013
P4, N=230, Active, not recruiting, Sponsor: Biogen Idec
- |||||||||| Copaxone 3TW (glatiramer acetate three times a week) / Teva
New P3 trial: Safety and Tolerability of Glatiramer Acetate (clinicaltrials.gov) - Jun 6, 2013
P3, N=210, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries
- || New P2/3 trial: Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis (clinicaltrials.gov) - Jun 6, 2013
P2/3, N=60, Completed, Sponsor: Royan Institute
- ||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
New P1 trial: Long-Term Efficacy and Safety of CT-P10 in Patients With RA (clinicaltrials.gov) - Jun 6, 2013
P1, N=102, Enrolling by invitation, Sponsor: Celltrion
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment open: Islet After Kidney Transplant for Type 1 Diabetes (clinicaltrials.gov) - Jun 6, 2013
P1/2, N=10, Recruiting, Sponsor: Virginia Commonwealth University
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | teriflunomide / Generic mfg.
Trial termination: TERACLES: Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta (clinicaltrials.gov) - Jun 5, 2013
P3, N=1455, Terminated, Sponsor: Sanofi
Active, not recruiting --> Recruiting Completed --> Terminated; Sponsor decision to prematurely stop the study, not linked to any safety concern.
- Clinical: Closing the Loop 24/7 in Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Jun 5, 2013
P=N/A, N=12, Not yet recruiting, Sponsor: University of Cambridge
- Clinical: A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients (clinicaltrials.gov) - Jun 5, 2013
P=N/A, N=240, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- ||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: DOSERA: Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA (clinicaltrials.gov) - Jun 5, 2013
P4, N=91, Completed, Sponsor: Pfizer
Completed --> Terminated; Sponsor decision to prematurely stop the study, not linked to any safety concern. N=72 --> 91
- New P2 trial: Artificial Pancreas Control System in an Outpatient Setting (clinicaltrials.gov) - Jun 5, 2013
P2, N=16, Active, not recruiting, Sponsor: Legacy Health System
- ||| Metoject (methotrexate autopen) / Medac
New P1 trial: Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient (clinicaltrials.gov) - Jun 5, 2013
P1, N=105, Completed, Sponsor: medac GmbH
- |||| Lantus (insulin glargine) / Sanofi
Trial completion: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin (clinicaltrials.gov) - Jun 5, 2013
P2, N=60, Completed, Sponsor: Sanofi
N=72 --> 91 Active, not recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Observational data, P4 data, Trial termination: A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China (clinicaltrials.gov) - Jun 4, 2013
P=N/A, N=26, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Terminated; This study was prematurely terminated due to low enrollment
- | Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
Trial initiation date: CEASE-MS: Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jun 4, 2013
P2a, N=16, Recruiting, Sponsor: RedHill Biopharma Limited
Recruiting --> Terminated; This study was prematurely terminated due to low enrollment Initiation date: Jan 2013 --> Jun 2013
- Humira (adalimumab) / Eisai, AbbVie
Observational data, P4 data, Enrollment change: A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China (clinicaltrials.gov) - Jun 4, 2013
P=N/A, N=26, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
Initiation date: Jan 2013 --> Jun 2013 N=500 --> 26
- Clinical: Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS) (clinicaltrials.gov) - Jun 4, 2013
P=N/A, N=34, Not yet recruiting, Sponsor: Hadassah Medical Organization
- | Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
Enrollment open: CEASE-MS: Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jun 4, 2013
P2a, N=16, Recruiting, Sponsor: RedHill Biopharma Limited
N=500 --> 26 Not yet recruiting --> Recruiting
- Trial completion: Investigating the Impact of Mode of Administration on Item Response (clinicaltrials.gov) - Jun 4, 2013
P=N/A, N=800, Completed, Sponsor: Stony Brook University
Not yet recruiting --> Recruiting Not yet recruiting --> Completed